MIALPHY
LIVE

Serial Number

98896645

Owner

RayzeBio, Inc.

Attorney

Xiomara Triana

Filing Date

Dec 11, 2024

Add to watchlist:

No watchlists yet
View on USPTO

MIALPHY Trademark

Serial Number: 98896645

MIALPHY is a trademark filed by RayzeBio, Inc. on December 11, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

RayzeBio, Inc. (54 trademarks)

5505 Morehouse Drive, Suite 300
San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

December 11, 2024

Registration Date

Not Registered

Published for Opposition

October 28, 2025

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs for human use being pharmaceutical preparations for the treatment of cancer; pharmaceutical anticoagulants for human use; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy preparations for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic preparations for human use for medical purposes; radiopharmaceutical preparations for human use in the nature of imaging and detection agents for diagnosing and monitoring cancer; biological preparations for human use in the nature of radio-isotope markers for therapeutic or diagnostic use; Pharmaceutical preparations for human use for the treatment of cystic fibrosis

Filing History

NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 23, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 28, 2025 NPUB
PUBLISHED FOR OPPOSITION
Oct 28, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 22, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 26, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 28, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 28, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 28, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 29, 2025 GNRN
NON-FINAL ACTION E-MAILED
May 29, 2025 GNRT
NON-FINAL ACTION WRITTEN
May 29, 2025 CNRT
ASSIGNED TO EXAMINER
May 29, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 11, 2024 NWOS
NEW APPLICATION ENTERED
Dec 11, 2024 NWAP